Safety and patient acceptability of BXCL501 for treating acute agitation in patients with bipolar disorder

被引：0
|
作者：
Zeller, Scott [1 ]
Citrome, Leslie [2 ]
Goldberg, Joseph [3 ]
Finman, Jeffrey [4 ]
De Vivo, Michael [5 ]
Yocca, Frank [5 ]
Risinger, Robert [5 ]
机构：
[1] Univ Calif Riverside, Riverside, CA 92521 USA
[2] New York Med Coll, Valhalla, NY 10595 USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Juniper Point Consulting Inc LLC, New York, NY USA
[5] BioXcel Therapeut, New Haven, CT USA
来源：
BIPOLAR DISORDERS | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
F20
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [1] Effect of BXCL501 up to 24 hours for treating a cute agitation in patients with bipolar disorder
    Preskorn, Sheldon
    Citrome, Leslie
    Zeller, Scott
    Finman, Jeffrey
    De Vivo, Michael
    Yocca, Frank
    Risinger, Robert
    BIPOLAR DISORDERS, 2021, 23 : 84 - 85
  • [2] LONGITUDINAL EFFICACY ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) FOR THE TREATMENT OF ACUTE AGITATION ASSOCIATED WITH SCHIZOPHRENIAAND BIPOLAR DISORDER
    Jonsson, F.
    Lagraauw, H.
    Lathia, C.
    Adedoyin, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S56 - S56
  • [3] BXCL501 demonstrates significant reduction in agitation across all mood states (depressed, hypomanic, manic) in patients with bipolar disorder
    Preskorn, Sheldon
    Goldberg, Joseph
    Finman, Jeffrey
    De Vivo, Michael
    Yocca, Frank
    Risinger, Robert
    BIPOLAR DISORDERS, 2021, 23 : 84 - 84
  • [4] Pharmacokinetics of dexmedetomidine after a single sublingual dose of BXCL501 in patients with agitation associated with schizophrenia
    Adedoyin, Adedayo
    Preskorn, Sheldon
    Lathia, Chetan
    BIPOLAR DISORDERS, 2021, 23 : 84 - 84
  • [5] POPULATION PHARMACOKINETIC ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) IN HEALTHY VOLUNTEERS AND ADULTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
    Lagraauw, H.
    Adedoyin, A.
    Lathia, C.
    Lindbom, L.
    Jonsson, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S74 - S74
  • [6] Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
    Faden, Justin
    Citrome, Leslie
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 2273 - 2283
  • [7] Management of acute agitation in patients with bipolar disorder - Efficacy and safety of intramuscular aripiprazole
    Zimbroff, Dan L.
    Marcus, Ronald N.
    Manos, George
    Stock, Elyse
    McQuade, Robert D.
    Auby, Philippe
    Oren, Dan A.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (02) : 171 - 176
  • [8] Safety, Efficacy, and Patient Acceptability of Aripiprazole in the Maintenance Treatment of Bipolar Disorder
    Paola Rapagnani, Maria
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2012, 4 : 131 - 144
  • [9] The Safety, Acceptability, and Effectiveness of Acupuncture as an Adjunctive Treatment for Acute Symptoms in Bipolar Disorder
    Dennehy, Ellen B.
    Schnyer, Rosa
    Bernstein, Ira H.
    Gonzalez, Robert
    Shivakumar, Geetha
    Kelly, Dorothy I.
    Snow, Diane E.
    Sureddi, Suresh
    Suppes, Trisha
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (06) : 897 - 905
  • [10] The safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for acute symptoms in bipolar disorder
    Dennehy, E. B.
    Schnyer, R.
    Bernstein, I. H.
    Gonzalez, R.
    Shivakumar, G.
    Kelly, D., I
    Snow, D. E.
    Sureddi, S.
    Suppes, T.
    Musil, R.
    DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR, 2011, 54 (04): : 21 - 22
12345